IL33 and hepatocellular carcinoma: Serum IL-33 levels in patients with advanced HCC [10] and metastatic HCC were significantly higher than those in patients with early-stage HCC or lung metastatic HCC [8, 10], suggesting that there is a significant relationship between systemically distributed IL-33 and disease progression [10].